South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei TopGene Biotechnology Co., Ltd to extend its presence in the Chinese market. Under this collaboration, TopGene will facilitate access to Novomics’ genomic testing services, including diagnostic kits and genetic information consulting, specifically for Chinese gastric cancer patients. Novomics will be responsible for the manufacturing and supply of these diagnostic kits.
Addressing a Critical Gap in Gastric Cancer Prognosis Prediction
Novomics’ gastric cancer genomic testing products offer a unique capability to predict prognosis, a service not currently available in China for this patient demographic. Given that China accounts for approximately 40% of the global gastric cancer patient population, this partnership is poised to make a significant impact.
Navigating Clinical Trials and Genetic Material Export Restrictions
The partnership with TopGene will also enable Novomics to conduct clinical trials for its products within China, aiding in the negotiation of the country’s restrictions on the export of human genetic materials.
TopGene: A Strong Commercial Partner for Novomics in China
TopGene is a formidable commercial partner for Novomics, providing molecular diagnostic analysis services for cancer through a network that spans over 1,300 hospitals across 30 provinces in China. The initial focus of this partnership will be on the regions of Zhejiang and Shanghai, offering a strategic entry point into the Chinese market for Novomics.-Fineline Info & Tech
